Related Experiment Video
Updated: Aug 19, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
IL-6 signaling orchestrates proteolytic hubs MuRF1 and Atrogin-1 in NSCLC induced sarcopenia
Gautam Kumar1,2, Shailza Singh1,2
1Systems Medicine Laboratory, BRIC- National Centre for Cell Science, NCCS Complex, Ganeshkhind, Pune, India.
Abstract:
Non-small cell lung cancer (NSCLC) is frequently associated with sarcopenia, a debilitating condition of muscle wasting driven by complex tumor-muscle cross-talk. To unravel the regulatory mechanisms underlying this phenotype, we reconstructed a comprehensive signaling network integrating inflammatory, anabolic, catabolic, and proteolytic pathways. The network was translated into a mechanistic mathematical model using ordinary differential equations, enabling dynamic simulations of pathway activity. Flux analysis revealed that only a limited number of reactions dominate system behavior, with cytoplasmic IL-6 export and SMAD2/3-4 mediated induction of MuRF1 and Atrogin-1 emerging as major control points for muscle protein breakdown. Crosstalk analysis identified these proteolytic regulators as central hubs, integrating signals from inflammatory cytokines, oxidative stress, and transcriptional modulators. Principal component analysis further confirmed that sarcopenic progression is governed by a compact regulatory core, with IL-6/STAT3, myostatin/SMAD, and FOXO/NF-κB pathways converging on MuRF1 and Atrogin-1. Experimental validation using immunofluorescence-based confocal microscopy demonstrated increased expression and altered localization of these ubiquitin ligases in C2C12 cells co-cultured with lung cancer lines, corroborating model predictions. Together, these findings provide a systems-level framework that transforms broad observations of inflammation into ranked therapeutic targets and support combined strategies aimed at blocking the IL-6/STAT3-myostatin/SMAD-FOXO1/3-MuRF1/Atrogin-1 axis to mitigate NSCLC-associated sarcopenia.
Insights
Non-small cell lung cancer (NSCLC) causes muscle wasting (sarcopenia) through complex signaling. Key muscle breakdown regulators, IL-6 and SMAD2/3, identified as therapeutic targets to combat this debilitating condition.
Area of Science:
- Oncology
- Systems Biology
- Muscle Physiology
Background:
- Non-small cell lung cancer (NSCLC) is strongly linked to sarcopenia, a severe muscle-wasting condition.
- Tumor-muscle cross-talk involves complex inflammatory, anabolic, catabolic, and proteolytic pathways.
- Understanding these pathways is crucial for developing effective treatments for NSCLC-associated sarcopenia.
Purpose of the Study:
- To reconstruct and model the signaling network driving NSCLC-associated sarcopenia.
- To identify key regulatory control points and therapeutic targets within this network.
- To experimentally validate the model's predictions regarding muscle protein breakdown.
Main Methods:
- Reconstruction of a comprehensive signaling network.
- Development of a mechanistic mathematical model using ordinary differential equations.
- Flux analysis, crosstalk analysis, and principal component analysis.
- Experimental validation using immunofluorescence-based confocal microscopy.
Main Results:
- Cytoplasmic IL-6 export and SMAD2/3-mediated induction of MuRF1 and Atrogin-1 are major control points for muscle protein breakdown.
- Proteolytic regulators MuRF1 and Atrogin-1 act as central hubs integrating inflammatory and stress signals.
- The IL-6/STAT3, myostatin/SMAD, and FOXO/NF-κB pathways converge on MuRF1 and Atrogin-1, governing sarcopenic progression.
- Experimental validation confirmed increased expression and altered localization of ubiquitin ligases in co-cultured cells.
Conclusions:
- A systems-level framework identifies key therapeutic targets for NSCLC-associated sarcopenia.
- Combined strategies blocking the IL-6/STAT3-myostatin/SMAD-FOXO1/3-MuRF1/Atrogin-1 axis are promising.
- This approach transforms broad observations of inflammation into ranked therapeutic strategies.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway
Abnormal Proliferation

